CBD-Focused Avicanna Taps Into European Market Via Exclusive Pharma Supply Deal

Avicanna Inc. (TSX:AVCN) (OTCQX:AVCNF) (FSE: 0NN) announced on Monday that it had reached an exclusive supply agreement for its two proprietary topical products with a multinational pharmaceutical company.

Avicanna did not the name of the company it was partnering with but said it manufactures and markets a wide range of pharmaceuticals across four continents and has an established commercial infrastructure in Europe that will be utilized for the initial launch of Avicanna’s products.

Aras Azadian, CEO of Avicanna, praised the move.

“We look forward to expanding our proprietary topical products into the European region and to be doing so through the utilization of our own international infrastructure for manufacturing,” Azadian said. “We are confident that through this strategic …

Full story available on Benzinga.com